LENZ Therapeutics, Inc.'s LNZ100 eye drops show strong phase 3 results for presbyopia, outperforming competitors. Click here ...

DelveInsight's "VUITY Market Size, Forecast, and Market Insight Report" highlights the details around VUITY, which is a ...

developed by Allergan (now part of AbbVie), is a 1.25% pilocarpine hydrochloride ophthalmic solution designed to treat presbyopia in adults. It acts as a cholinergic muscarinic receptor agonist ...

Alcon ALC recently announced that its Clareon Vivity intraocular lens (IOL), featuring extended depth of focus (EDOF) ...

Individuals with mild to moderate presbyopia who were treated with CSF-1 were able to achieve and maintain functional vision for at least 5 hours after two doses, according to a presenter at Academy ...

LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day”. LENZ is headquartered in San Diego, California. For more information, ...

LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day”. LENZ is headquartered in San Diego, California. For more ...

LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day”. LENZ is headquartered in San Diego, California. For more ...

LENZ is dedicated to offering a comprehensive solution for those affected by presbyopia, a condition impacting millions globally. LENZ Therapeutics is focusing on the development of the first and ...

ATHENS, Greece — Allogenic corneal inlays can be a safe solution for mild hyperopia and emmetropic presbyopia, according to an expert at the ESCRS winter meeting. The FDA granted fast track ...